2023
DOI: 10.3389/fpsyt.2023.1135828
|View full text |Cite
|
Sign up to set email alerts
|

Recommendations for selection and adaptation of rating scales for clinical studies of rapid-acting antidepressants

Abstract: The novel mechanisms of action (MOA) derived from some recently introduced molecular targets have led to regulatory approvals for rapid acting antidepressants (RAADs) that can generate responses within hours or days, rather than weeks or months. These novel targets include the N-methyl-D-glutamate receptor antagonist ketamine, along with its enantiomers and various derivatives, and the allosteric modulators of gamma-aminobutyric acid (GABA) receptors. There has also been a strong resurgence in interest in psyc… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 56 publications
0
3
0
Order By: Relevance
“…Certainly, not all depressed individuals have the same depressive symptoms at baseline and the dynamic nature of a therapeutic response to RAADs could potentially result in a rapid alleviation of certain symptoms, e.g. improvements in subjective mood, while leaving some other functional aspects less improved, resulting in a heterogeneity of symptom resolution and a sense of uncertainty in raters ( 36 ).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Certainly, not all depressed individuals have the same depressive symptoms at baseline and the dynamic nature of a therapeutic response to RAADs could potentially result in a rapid alleviation of certain symptoms, e.g. improvements in subjective mood, while leaving some other functional aspects less improved, resulting in a heterogeneity of symptom resolution and a sense of uncertainty in raters ( 36 ).…”
Section: Discussionmentioning
confidence: 99%
“…provide an excellent summary on adaptations to the standard rating instruments allowing to reflect short-term changes in which RAADs act, as well as implementing novel rating measures. Critically, they also discuss limitations and challenges to the currently used rating measures including any conceptual biases of raters ( 36 ).…”
Section: Introductionmentioning
confidence: 99%
“…The MADRS and Hamilton Depression Scales are the most commonly used instruments to evaluate mood responses to ketamine in patients with TRD ( Yavorsky et al, 2023 ). The HADS is another validated scale ( Bjelland et al, 2002 ), and although it has been used to evaluate the antidepressant effects of ketamine ( Irwin et al, 2013 ; Jafarinia et al, 2016 ; Moitra et al, 2016 ; Voute et al, 2023 ; Zhou et al, 2021 ), this has been mainly in patients with medical or surgical comorbidities.…”
Section: Discussionmentioning
confidence: 99%